{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:51:55Z","timestamp":1789779115491,"version":"4.0.1"},"reference-count":45,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Clinical pharmacists play a vital role in reviewing anticancer regimens, dose calculations, managing drug-related problems, and monitoring adverse drug reactions. The aim of this study was to identify, classify and reduce drug-related problems in patients with neoplastic disease hospitalized in the pediatric hematology-oncology clinic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The study was a prospective, interventional study consisting of observation and intervention periods conducted for five months, from April 2024 to August 2024. During the intervention period of the study, clinical pharmacist recommendations for drug-related problems were presented to the healthcare team. Drug-related problems was used in Pharmaceutical Care Network Version 9.1 and were classified according to their clinical significance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 80 patients were included in the study. The median (interquartile range) age of all patients was 7.5 years (4-12.75) and 61.3% were boy. The most common malignancies are acute lymphoblastic leukemia (32.5%) and medulloblastoma (10%). A total of 457 drug-related problems were detected in all periods, 147 of the 457 drug-related problems were related to \u2018\u2018not clinically significant\u2019\u2019 drug-drug interactions. In the intervention period, the frequency of all drug-related problems decreased by 56.3% (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). The most common causes of drug-related problems were drug-drug interactions (47.7%), other causes (13.8%), and indication no treatment (9.1%). During the intervention period, recommendations were made for 66 of the 138 drug-related problems identified, and all of these recommendations (100%) were accepted by physicians. The intervention period recommendations were mostly in the form of drug dose change (35.3%), change in instructions for use (27.4%), drug change (11.77%) and drug paused\/stopped (11.77%). 37% of patients who received chemotherapy had adverse events during and after chemotherapy, and during their hospital stay. The most common chemotherapy-related adverse events were leukopenia (20%), lymphopenia (17.5%), and neutropenia (13.8%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>A high incidence of drug-related problems was detected in patients with neoplastic disease hospitalized in the pediatric hematology-oncology clinic. All of the clinical pharmacist's recommendations were accepted by the healthcare team.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552251383020","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T19:54:23Z","timestamp":1759262063000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Reducing drug-related problems in hospitalized pediatric cancer patients through clinical pharmacist interventions: An interventional study from Turkey"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7048-8879","authenticated-orcid":false,"given":"\u00d6mer Faruk","family":"\u00d6zkanl\u0131","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Marmara University Faculty of Pharmacy, Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7940-2640","authenticated-orcid":false,"given":"Ahmet","family":"Ko\u00e7","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology Oncology, Marmara University Faculty of Medicine, Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7707-3035","authenticated-orcid":false,"given":"Nur\u015fah","family":"Eker","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology Oncology, Marmara University Faculty of Medicine, Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7445-3235","authenticated-orcid":false,"given":"Mesut","family":"Sancar","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Marmara University Faculty of Pharmacy, Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"e_1_3_4_2_2","volume-title":"SPEC\u2013Lanzkowsky's Manual of Pediatric Hematology and Oncology, 12-Month Access, eBook: SPEC\u2013Lanzkowsky's Manual of Pediatric Hematology and Oncology, 12-Month Access, eBook","author":"Fish JD","year":"2021","unstructured":"Fish JD, Lipton JM, Lanzkowsky P. SPEC\u2013Lanzkowsky's Manual of Pediatric Hematology and Oncology, 12-Month Access, eBook: SPEC\u2013Lanzkowsky's Manual of Pediatric Hematology and Oncology, 12-Month Access, eBook. 7th ed. Chennai, India: Academic Press, 2021.","edition":"7"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30022-X"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.e22020"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000000044"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26897"},{"key":"e_1_3_4_7_2","first-page":"479","article-title":"The impact of clinical pharmacy services in a tertiary care center specialized in pediatric hemato-oncology","volume":"9","author":"Gradwohl C","year":"2022","unstructured":"Gradwohl C, Engstler G, Anditsch M, et al. The impact of clinical pharmacy services in a tertiary care center specialized in pediatric hemato-oncology. Children (Basel) 2022; 9: 479.","journal-title":"Children (Basel)"},{"key":"e_1_3_4_8_2","first-page":"8","article-title":"Dosing considerations in pediatric oncology","volume":"38","author":"Ceja ME","year":"2013","unstructured":"Ceja ME, Christensen A, Yang S. Dosing considerations in pediatric oncology. US Pharm 2013; 38: 8\u201311.","journal-title":"US Pharm"},{"key":"e_1_3_4_9_2","unstructured":"ALL IC-BFM. A Randomized Trial of the I-BFM-SG for the Management of Childhood non-B Acute Lymphoblastic Leukemia https:\/\/www.bialaczka.org\/wp-content\/uploads\/2016\/10\/ALLIC_BFM_2009.pdf (2009 assessed 17 December 2024). 2009."},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1284"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0085"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219892666"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2024.2411255"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/4323189"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220934167"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/6785835"},{"key":"e_1_3_4_17_2","first-page":"107815522412306","article-title":"Analysis of pharmaceutical interventions in chemotherapy prescriptions of adult and pediatric patients at an oncology reference institute","volume":"31","author":"Venancio R","year":"2024","unstructured":"Venancio R, Magliano E, Barreto EDG. Analysis of pharmaceutical interventions in chemotherapy prescriptions of adult and pediatric patients at an oncology reference institute. J Oncol Pharm Pract 2024; 31: 10781552241230630.","journal-title":"J Oncol Pharm Pract"},{"key":"e_1_3_4_18_2","unstructured":"American College of Clinical Pharmacy. Definition of Clinical Pharmacy https:\/\/www.accp.com\/stunet\/compass\/definition.aspx (2008 accessed 17 December 2024)."},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1177\/10781552241230631"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26410"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.5863\/1551-6776-17.3.281"},{"key":"e_1_3_4_22_2","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm (2017 accessed 28 December 2024)."},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1982.tb01361.x"},{"key":"e_1_3_4_24_2","unstructured":"Bethesda M. Adverse Drug Reaction Probability Scale (Naranjo) in Drug Induced Liver Injury https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548069\/ (2019 accessed 28 December 2024)."},{"key":"e_1_3_4_25_2","first-page":"806","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","author":"von Elm E","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, et al. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2007; 335: 806\u2013808.","journal-title":"J Clin Epidemiol"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare10040751"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.2147\/DHPS.S220081"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1177\/10781552211068139"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.7454\/psr.v6i1.3966"},{"key":"e_1_3_4_30_2","first-page":"1007","article-title":"Assessment of drug-related problems in pediatric inpatients by clinical pharmacist-led medication review: An observational study","volume":"26","author":"\u015eahin Y","year":"2022","unstructured":"\u015eahin Y, Nuhoglu C, Okuyan B, et al. Assessment of drug-related problems in pediatric inpatients by clinical pharmacist-led medication review: An observational study. J Res Pharm 2022; 26: 1007\u20131015.","journal-title":"J Res Pharm"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12291-w"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1590\/S1679-45082016AO3667"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155208093929"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220950416"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.26650\/IstanbulJPharm.2020.0041"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1177\/10781552221079786"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.21608\/ejhm.2022.260758"},{"key":"e_1_3_4_38_2","article-title":"Medication review for hospitalized pediatric patient: clinical pharmacist interventions","volume":"14","author":"I\u015f\u0131k MN","year":"2020","unstructured":"I\u015f\u0131k MN, Dalg\u0131\u00e7 N, Okuyan B, et al. Medication review for hospitalized pediatric patient: clinical pharmacist interventions. J Pediatr Inf 2020; 14: e218\u2013e224.","journal-title":"J Pediatr Inf"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1177\/10781552211041037"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.5863\/1551-6776-28.3.212"},{"key":"e_1_3_4_41_2","first-page":"457","article-title":"Impact of clinical pharmacy services in a hematology\/oncology inpatient setting","volume":"35","author":"Delpeuch A","year":"2015","unstructured":"Delpeuch A, Leveque D, Gourieux B, et al. Impact of clinical pharmacy services in a hematology\/oncology inpatient setting. Anticancer Res 2015; 35: 457\u2013460.","journal-title":"Anticancer Res"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.4103\/0976-0105.195083"},{"key":"e_1_3_4_43_2","first-page":"34","article-title":"Evaluation of potential drug interactions in hospitalized pediatric oncology patients","volume":"45","author":"Ribeiro E","year":"2021","unstructured":"Ribeiro E, Pedrosa S. Evaluation of potential drug interactions in hospitalized pediatric oncology patients. O Mundo da Sa\u00fade 2021; 45: 34\u201344.","journal-title":"O Mundo da Sa\u00fade"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.2147\/DHPS.S254644"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.3390\/ph17010106"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.670945"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251383020","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552251383020","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251383020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:31:48Z","timestamp":1777689108000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552251383020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":45,"alternative-id":["10.1177\/10781552251383020"],"URL":"https:\/\/doi.org\/10.1177\/10781552251383020","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"article-number":"10781552251383020"}}